🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal diseases in Japan; ARDX up 13% premarket

Published 11/28/2017, 09:00 AM
© Reuters.  Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal diseases in Japan; ARDX up 13% premarket
ARDX
-
  • Ardelyx (NASDAQ:ARDX) and Kyowa Hakko Kirin (OTCPK:KYKOF) announces that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.
  • Under the terms of the agreement, Ardelyx will receive a $30M upfront payment and is eligible to receive additional milestones worth up to $130M. Ardelyx is also eligible to receive high-teen royalties throughout the term of the agreement.
  • Kyowa Hakko Kirin will have the exclusive rights to develop, market and commercialize tenapanor in Japan.
  • Tenapanor is an oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis.
  • Shares of ARDX are up 13% premarket on light volume.
  • Now read: Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.